TN2015000237A1 - Modulateurs de recepteurs d'androgenes selectifs nouveaux - Google Patents
Modulateurs de recepteurs d'androgenes selectifs nouveauxInfo
- Publication number
- TN2015000237A1 TN2015000237A1 TNP2015000237A TN2015000237A TN2015000237A1 TN 2015000237 A1 TN2015000237 A1 TN 2015000237A1 TN P2015000237 A TNP2015000237 A TN P2015000237A TN 2015000237 A TN2015000237 A TN 2015000237A TN 2015000237 A1 TN2015000237 A1 TN 2015000237A1
- Authority
- TN
- Tunisia
- Prior art keywords
- straight
- alkyl
- hydrogen
- branched
- branched chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
La présente invention concerne un composé de formule 1, 2 ou 3 : dans laquelle A est N ou -CR0 --, R0 étant un groupe hydrogène, alkyle à chaîne linéaire ou ramifiée en C1 -C6, etc.; Z est -CRe --, ou, -N--, Re étant un groupe hydrogène, alkyle à chaîne linéaire ou ramifiée en C1 -C6, etc.; R1 est un groupe hydrogène, alkyle à chaîne linéaire ou ramifiée en C1 -C6, etc.; R2 sont indépendamment un groupe hydrogène ou alkyle à chaîne linéaire ou ramifiée en C1 -C6; R3 et R4 sont indépendamment un groupe hydrogène, alkyle à chaîne linéaire ou ramifiée en C1 -C6, etc.; R5 et R6 sont indépendamment un groupe hydrogène ou alkyle à chaîne linéaire ou ramifiée en C1 -C6, etc.; R8 est un groupe hydrogène, alkyle à chaîne linéaire ou ramifiée en C1 -C6, etc.; R9 et R10 sont indépendamment un groupe hydrogène ou alkyle à chaîne linéaire ou ramifiée en C1 -C6, etc.; Q est --CO--, --(CH2 )q --, --(CHRS )q --, ou -(CRS Rt )q--, où RS et Rt sont indépendamment un groupe alkyle, aryle, alkylaryle, hétéroaryle ou alkylhétéroaryle à chaîne linéaire ou ramifiée en C1 -C6; où q vaut 0, 1, 2 ou 3; et où n vaut 0, 2, 3, 4 ou 5; ou son sel pharmaceutiquement acceptable, des compositions contenant lesdits composés; et les utilisations desdits composés dans le traitement de diverses maladies, en particulier celles affectées ou médiées par le récepteur androgénique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261732617P | 2012-12-03 | 2012-12-03 | |
PCT/IB2013/060381 WO2014087298A1 (fr) | 2012-12-03 | 2013-11-25 | Nouveaux modulateurs androgéniques sélectifs |
Publications (1)
Publication Number | Publication Date |
---|---|
TN2015000237A1 true TN2015000237A1 (fr) | 2016-10-03 |
Family
ID=49955433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2015000237A TN2015000237A1 (fr) | 2012-12-03 | 2015-06-01 | Modulateurs de recepteurs d'androgenes selectifs nouveaux |
Country Status (34)
Country | Link |
---|---|
US (1) | US9328104B2 (fr) |
EP (1) | EP2925725B1 (fr) |
JP (1) | JP6039100B2 (fr) |
KR (1) | KR101745225B1 (fr) |
CN (1) | CN104854093B (fr) |
AP (1) | AP2015008444A0 (fr) |
AR (1) | AR093697A1 (fr) |
AU (1) | AU2013353723B2 (fr) |
BR (1) | BR112015011897B1 (fr) |
CA (1) | CA2891234C (fr) |
CL (1) | CL2015001495A1 (fr) |
CO (1) | CO7400864A2 (fr) |
CR (1) | CR20150290A (fr) |
CU (1) | CU20150054A7 (fr) |
DK (1) | DK2925725T3 (fr) |
DO (1) | DOP2015000132A (fr) |
EA (1) | EA026562B1 (fr) |
ES (1) | ES2609596T3 (fr) |
HK (1) | HK1209744A1 (fr) |
IL (1) | IL239076B (fr) |
MA (1) | MA38114A1 (fr) |
MD (1) | MD20150049A2 (fr) |
MX (1) | MX368898B (fr) |
MY (1) | MY176727A (fr) |
NZ (1) | NZ707752A (fr) |
PE (1) | PE20151158A1 (fr) |
PH (1) | PH12015501215B1 (fr) |
SG (1) | SG11201503580WA (fr) |
TN (1) | TN2015000237A1 (fr) |
TW (1) | TWI518083B (fr) |
UA (1) | UA110766C2 (fr) |
UY (1) | UY35158A (fr) |
WO (1) | WO2014087298A1 (fr) |
ZA (1) | ZA201503517B (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3143019B1 (fr) | 2014-05-15 | 2020-12-16 | Pfizer Inc | Forme cristalline du 6-[(4r)-4-méthyl -1,2-dioxydo-1,2,6-thiadiazinan -2-yle]isoquinoline-1-carbonitrile |
RU2016146826A (ru) | 2014-05-30 | 2018-07-04 | Пфайзер Инк. | Производные карбонитрилов как селективные модуляторы андрогенового рецептора |
TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
CN107573270B (zh) * | 2017-09-29 | 2019-11-29 | 河南师范大学 | 一种α-甲酰基吡咯烷类化合物的合成方法 |
CN110372628B (zh) * | 2019-07-09 | 2021-04-02 | 武汉大学 | 内磺酰胺类化合物及其制备方法 |
US20220315568A1 (en) * | 2019-09-12 | 2022-10-06 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
WO2023275715A1 (fr) * | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Métabolites de modulateurs sélectifs du récepteur des androgènes |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE638650C (de) | 1934-06-08 | 1936-11-20 | I G Farbenindustrie Akt Ges | Verfahren zur Darstellung von 3, 4-Dioxyphenylmonoalkylaminobutanolen-1 |
US2482055A (en) | 1948-02-11 | 1949-09-13 | American Cyanamid Co | Aureomycin and preparation of same |
US2715141A (en) | 1952-03-27 | 1955-08-09 | Delmar Chem | Optically active isopropyl arterenol |
US3377364A (en) | 1957-09-23 | 1968-04-09 | Upjohn Co | 6-methyl-17alpha-hydroxyprogesterone, the lower fatty acid 17-acylates and methods for producing the same |
US3332940A (en) | 1959-08-28 | 1967-07-25 | British Drug Houses Ltd | Process for the preparation of 17alpha-acyloxy-6-methyl-16-methylene-4, 6-pregnadiene-3, 20-diones and intermediates obtained therefrom |
US3359287A (en) | 1959-11-16 | 1967-12-19 | Upjohn Co | 16-methylene-17alpha-hydroxy progesterones and derivatives thereof |
DE1275069B (de) | 1960-02-15 | 1968-08-14 | Boehringer Sohn Ingelheim | 1-(3', 5'-Dihydroxyphenyl)-1-hydroxy-2-isopropylaminoalkane und Verfahren zu ihrer Herstellung |
DE1158966B (de) | 1961-04-29 | 1963-12-12 | Schering Ag | Verfahren zur Herstellung von 6-Chlor-1, 2ª-methylen-í¸-17ª-hydroxyprogesteronestern |
NL130078C (fr) | 1963-06-11 | |||
US3239345A (en) | 1965-02-15 | 1966-03-08 | Estrogenic compounds and animal growth promoters | |
DE1618005A1 (de) | 1966-09-22 | 1971-09-09 | Thomae Gmbh Dr K | Verfahren zur Herstellung von neuen Amino-dihalogen-phenyl-aethylaminen |
GB1200886A (en) | 1966-09-23 | 1970-08-05 | Allen & Hanburys Ltd | Phenylaminoethanol derivatives |
US4138581A (en) | 1969-04-01 | 1979-02-06 | Sterling Drugs Inc. | 3(Hydroxy or hydroxymethyl)-4(hydroxy)-α-(aminomethyl)benzyl alcohols |
US3705169A (en) | 1970-11-05 | 1972-12-05 | Smith Kline French Lab | Hydroxyphenyl-2-piperidinylcarbinols |
US3763232A (en) | 1971-01-11 | 1973-10-02 | Smith Kline French Lab | Alpha-aminoalkyl-4-hydroxy-3-ureidobenzyl alcohols |
US3700681A (en) | 1971-02-16 | 1972-10-24 | Pfizer | 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-aminoethyl)pyridines |
BE788737A (fr) | 1971-09-13 | 1973-01-02 | Hokuriku Pharmaceutical | Procede de preparation de derives de l'alcool o-chlorobenzylique |
BE789629A (fr) | 1971-10-05 | 1973-04-03 | Sandoz Sa | Nouveaux derives de la pleuromutiline, leur preparation et leurapplication en therapeutique |
US3919290A (en) | 1972-10-03 | 1975-11-11 | Sandoz Ltd | Substituted 14-desoxy-mutilins |
US3839557A (en) | 1972-01-24 | 1974-10-01 | Lilly Co Eli | Antibiotics monensin and a204 for improving ruminant feed efficiency |
US3939265A (en) | 1972-05-10 | 1976-02-17 | Jean Andre Grandadam | Novel zootechnical compositions |
US4119710A (en) | 1972-12-18 | 1978-10-10 | Boehringer Ingelheim Gmbh | Bronchospasmolytic 1-(p-amino-phenyl)-2-amino-ethanols-(1) and salts |
US4022776A (en) | 1974-01-31 | 1977-05-10 | Otsuka Pharmaceutical Company Limited | 5-[1-Hydroxy-2-(substituted-amino)]ethyl-8-hydroxycarbostyril derivatives |
US4048268A (en) | 1975-02-19 | 1977-09-13 | Eli Lilly And Company | Stabilization method |
US3987194A (en) | 1975-05-12 | 1976-10-19 | E. R. Squibb & Sons, Inc. | Use of pleuromutilin derivatives for the treatment of swine dysentery |
US3995027A (en) | 1975-06-04 | 1976-11-30 | Eli Lilly And Company | Anti-viral method in animals |
FR2388560A1 (fr) | 1977-04-27 | 1978-11-24 | Roussel Uclaf | Nouvelles compositions zootechniques renfermant d'une part le zeranol et d'autre part un steroide 4,9,11 trienique |
US4154748A (en) | 1978-01-20 | 1979-05-15 | The Upjohn Company | Phosphate catalyzed acylation of steroidal tertiary alcohols |
US4283388A (en) | 1979-12-26 | 1981-08-11 | Eli Lilly And Company | Method for treating colibacillosis in pigs with tylosin apramycin compositions |
ATE7689T1 (de) | 1980-07-09 | 1984-06-15 | Aktiebolaget Draco | 1-(dihydroxyphenyl)-2-amino-aethanol-derivate, verfahren und mittel zu ihrer herstellung sowie diese derivate enthaltende mittel. |
US5643967A (en) | 1983-01-31 | 1997-07-01 | Eli Lilly And Company | Growth promotion |
IE60964B1 (en) | 1986-12-11 | 1994-09-07 | Roussel Uclaf | Zootechnical compositions containing a beta-adrenergic |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
DE4014252A1 (de) | 1990-05-04 | 1991-11-07 | Boehringer Ingelheim Vetmed | Enantiomerentrennung von cimaterol, (-)-cimaterol und dessen verwendung als arzneimittel oder als leistungsfoerderer |
GB9107196D0 (en) | 1991-04-05 | 1991-05-22 | Sandoz Ag | Improvements in or relating to organic compounds |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035298A1 (fr) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing-gum contenant des agents medicamenteux actifs |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
AUPO776897A0 (en) | 1997-07-09 | 1997-07-31 | Csl Limited | A method of achieving production gains in livestock and agents useful for same |
JP4426792B2 (ja) * | 2002-08-12 | 2010-03-03 | 武田薬品工業株式会社 | 縮合ベンゼン誘導体および用途 |
JP2007505164A (ja) * | 2003-06-10 | 2007-03-08 | スミスクライン ビーチャム コーポレーション | アンドロゲン、グルココルチコイド、ミネラルコルチコイドおよびプロゲステロン受容体のモジュレーターとしての1−アミノナフタレン類 |
CN1838956A (zh) * | 2003-08-22 | 2006-09-27 | 配体药物公司 | 作为雄激素受体调节剂化合物的6-环氨基-2-喹啉酮衍生物 |
CA2566942A1 (fr) * | 2004-05-17 | 2005-12-08 | Acadia Pharmaceuticals Inc. | Modulateurs des recepteurs d'androgenes et methodes de traitement de maladies utilisant ceux-ci |
PT2222636E (pt) | 2007-12-21 | 2013-07-16 | Ligand Pharm Inc | Moduladores seletivos de recetores de andrógeno (sarms) e suas utilizações |
US8067448B2 (en) * | 2008-02-22 | 2011-11-29 | Radius Health, Inc. | Selective androgen receptor modulators |
-
2013
- 2013-11-25 CA CA2891234A patent/CA2891234C/fr active Active
- 2013-11-25 KR KR1020157017712A patent/KR101745225B1/ko active IP Right Grant
- 2013-11-25 BR BR112015011897-6A patent/BR112015011897B1/pt not_active IP Right Cessation
- 2013-11-25 MD MDA20150049A patent/MD20150049A2/ro not_active Application Discontinuation
- 2013-11-25 DK DK13820949.9T patent/DK2925725T3/en active
- 2013-11-25 WO PCT/IB2013/060381 patent/WO2014087298A1/fr active Application Filing
- 2013-11-25 PE PE2015000720A patent/PE20151158A1/es not_active Application Discontinuation
- 2013-11-25 MY MYPI2015701459A patent/MY176727A/en unknown
- 2013-11-25 AP AP2015008444A patent/AP2015008444A0/xx unknown
- 2013-11-25 NZ NZ707752A patent/NZ707752A/en not_active IP Right Cessation
- 2013-11-25 MA MA38114A patent/MA38114A1/fr unknown
- 2013-11-25 UA UAA201504472A patent/UA110766C2/uk unknown
- 2013-11-25 AU AU2013353723A patent/AU2013353723B2/en not_active Ceased
- 2013-11-25 ES ES13820949.9T patent/ES2609596T3/es active Active
- 2013-11-25 SG SG11201503580WA patent/SG11201503580WA/en unknown
- 2013-11-25 CN CN201380062913.XA patent/CN104854093B/zh not_active Expired - Fee Related
- 2013-11-25 EP EP13820949.9A patent/EP2925725B1/fr active Active
- 2013-11-25 MX MX2015006987A patent/MX368898B/es active IP Right Grant
- 2013-11-25 EA EA201590757A patent/EA026562B1/ru not_active IP Right Cessation
- 2013-11-25 JP JP2015544586A patent/JP6039100B2/ja not_active Expired - Fee Related
- 2013-11-28 TW TW102143554A patent/TWI518083B/zh not_active IP Right Cessation
- 2013-11-29 UY UY0001035158A patent/UY35158A/es not_active Application Discontinuation
- 2013-12-02 AR ARP130104447A patent/AR093697A1/es unknown
- 2013-12-02 US US14/093,812 patent/US9328104B2/en active Active
-
2015
- 2015-05-19 ZA ZA2015/03517A patent/ZA201503517B/en unknown
- 2015-05-28 IL IL239076A patent/IL239076B/en active IP Right Grant
- 2015-05-29 CR CR20150290A patent/CR20150290A/es unknown
- 2015-05-29 PH PH12015501215A patent/PH12015501215B1/en unknown
- 2015-05-29 CU CUP2015000054A patent/CU20150054A7/es unknown
- 2015-06-01 TN TNP2015000237A patent/TN2015000237A1/fr unknown
- 2015-06-02 CO CO15126416A patent/CO7400864A2/es unknown
- 2015-06-03 CL CL2015001495A patent/CL2015001495A1/es unknown
- 2015-06-03 DO DO2015000132A patent/DOP2015000132A/es unknown
- 2015-10-28 HK HK15110628.2A patent/HK1209744A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2015000237A1 (fr) | Modulateurs de recepteurs d'androgenes selectifs nouveaux | |
EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
MA35128B1 (fr) | Nouveaux dérivés d'imidazole utiles pour le traitement de l'arthrite | |
MA37519B1 (fr) | Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1 | |
MA39211B1 (fr) | Composés tricycliques comme agents anti-cancers | |
PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
AR068116A1 (es) | Compuestos 8-azabiciclo[3.2.1]octil-2-hidroxibenzamida como antagonistas de receptores opioides mu, proceso de preparacion de los mismos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de disfunciones intestinales inducidas por opioides o ileo posquirurgico. | |
EA201490445A1 (ru) | Циклопропанаминовое соединение | |
EA200970510A1 (ru) | Гетеромоноциклическое соединение и его применение | |
MX2016015467A (es) | Derivados de carbonitrilo como moduladores selectivos del receptor de androgenos. | |
MA30524B1 (fr) | Agent de lutte antiparasite contenant un nouveau derive de pyridyl-methanamine ou un sel de celui-ci | |
ATE540037T1 (de) | Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten | |
IN2014DN07082A (fr) | ||
MA20150429A1 (fr) | Benzamides | |
BR112013010850A8 (pt) | Composto de etinilfenilamidina ou sal do mesmo, método para produzir o mesmo e fungicida para uso agrícola e em horticultura | |
PE20141169A1 (es) | Derivados de etinilo | |
MA33675B1 (fr) | Composé indazole et pyrazolopyridine en tant qu'antagonistes du récepteur ccr1 | |
PH12015502684A1 (en) | New compounds having triple activities of thrombolysis, antithrombotic and radical scavenging, and synthesis, nano-structure and use thereof | |
MY195881A (en) | Griseofulvin Compound | |
PE20141168A1 (es) | Derivados de pirazolidin-3-ona | |
TN2013000546A1 (en) | Microbiocidal heterocycles | |
MA41975B1 (fr) | Derives d'aminohydrothiazine fusionnee contenant du tetrahydrofurane utiles dans le traitement de la maladie d'alzheimer | |
PH12018501586A1 (en) | Novel biphosphonic acid compound | |
PE20141555A1 (es) | Derivados de etinilo | |
RU2013110377A (ru) | Новые производные 6,7-двузамещенного изохинолина и их применение |